Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 4/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL3677190 | 0.87 | CA5A (0.50) | TP53CA5ACA5BBLMCYP2C19 | |
| Sulfuric Acid SCHEMBL8766489 | 0.87 | CA5A (0.50) | TP53CA5ACA5BBLMCYP2C19 | |
| Sulfuric Acid SCHEMBL921788 | 0.87 | — | — | |
| Sulfuric Acid SCHEMBL28919815 | 0.83 | — | — | |
| Sulfuric Acid SCHEMBL6509471 | 0.83 | CA5A (0.46) | TP53CA5ACA5BBLMCYP2C19 | |
| Sulfuric Acid SCHEMBL28158068 | 0.83 | — | — | |
| Ethylamine SCHEMBL19327142 | 0.79 | — | — | |
| Sulfuric Acid SCHEMBL28557396 | 0.78 | TP53 (0.42) | TP53CA5ACA5BBLMCYP2C19 | |
| Sulfuric Acid SCHEMBL28521927 | 0.78 | CA5A (0.40) | TP53CA5ACA5BBLMCYP2C19 | |
| Sulfamate SCHEMBL18543083 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822259-B1 | METHOD FOR SYNTHESIZING VALSARTAN | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2025-08-27 | — | — | EP | claimed |
| US-11434210-B2 | Method for synthesizing valsartan | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2022-09-06 | — | — | US | claimed |
| EP-3822259-A1 | METHOD FOR SYNTHESIZING VALSARTAN | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2021-05-19 | — | — | EP | claimed |
| EP-3822259-B1 | METHOD FOR SYNTHESIZING VALSARTAN | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-11434210-B2 | Method for synthesizing valsartan | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2022-09-06 | — | — | US | disclosed |
| EP-3822259-A1 | METHOD FOR SYNTHESIZING VALSARTAN | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434210-B2 | Method for synthesizing valsartan | REN, ACE, AGT | TP53 2907/4885CA5A 3037/4885CA5B 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.